{
  "title": "Paxlovid May Reduce Risk of Long Covid in Eligible Patients, Study Finds",
  "link": "https://www.nytimes.com/2022/11/07/health/paxlovid-long-covid.html",
  "guid": "https://www.nytimes.com/2022/11/07/health/paxlovid-long-covid.html",
  "atom:link": "",
  "description": "The research looked at patients who qualified for the antiviral through age or health conditions. Those who took it shortly after infection were 26 percent less likely to have symptoms 90 days later.",
  "dc:creator": "Pam Belluck",
  "pubDate": "Mon, 07 Nov 2022 19:36:11 +0000",
  "category": [
    "Long Covid",
    "Paxlovid (Drug)",
    "Coronavirus (2019-nCoV)",
    "Research",
    "Veterans",
    "Disease Rates",
    "Veterans Health Administration"
  ],
  "media:content": "",
  "media:credit": "Joe Raedle/Getty Images",
  "media:description": "Participants who took Paxlovid within five days after their infection were 26 percent less likely to have a wide range of post-Covid symptoms 90 days after infection."
}